{"id":"W4415877972","doi":"10.51731/cjht.2025.1282","title":"Risankizumab (Skyrizi)","year":2025,"lang":"","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Ulcerative colitis; Drug; Population; Disease; Orphan drug; Tofacitinib","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004109022,0.0003730598,0.0004582428,0.0006184814,0.0002848184,0.0006670674,0.0004409716,0.0007314333,0.01845646],"category_scores_gemma":[0.0006419788,0.0001234087,0.0005554455,0.0003114402,0.0002269401,0.0002645936,0.0005044182,0.001253297,0.01121218],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00106047,"about_ca_system_score_gemma":0.001291402,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003533892,"about_ca_topic_score_gemma":0.006914593,"domain_scores_codex":[0.9996701,0.00003954406,0.00002555712,0.00004737135,0.0001417149,0.00007580077],"domain_scores_gemma":[0.9997423,0.00002434708,0.00005380315,0.00001724245,0.00006885263,0.00009344179],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.003042456,0.0005473284,0.004007834,0.001505906,0.0001697301,0.001066107,0.00007429726,0.0006419889,0.02047887,0.003968813,0.2158666,0.74863],"study_design_scores_gemma":[0.003641974,0.003274071,0.0114465,0.0005214083,0.0001935716,0.005539283,0.00005064721,0.0005784162,0.01137546,0.0009772693,0.9623628,0.00003875177],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"other","genre_gemma":"other","genre_scores_codex":[0.1412225,0.317082,0.007674978,0.02603018,0.005520304,0.001701443,0.01922041,0.006263878,0.4752842],"genre_scores_gemma":[0.6551802,0.07190656,0.008803868,0.0180768,0.001927521,0.0005744137,0.02925401,0.0002181912,0.2140585],"genre_candidate":"other","genre_consensus":"other","teacher_disagreement_score":0.01845646,"threshold_uncertainty_score":0.06174302,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008277496548169965,"score_gpt":0.2622596702949909,"score_spread":0.253982173746821,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}